Kessarin Thanapirom
Appearances
- DateMay 19, 2024BACKGROUND: Atezolizumab plus bevacizumab (ATEZO/BEV) and lenvatinib (LEN) have shown efficacy as first-line systemic treatments for unresectable hepatocellular carcinoma (HCC) in previous studies…
- DateMay 18, 2024Variceal bleeding in hepatocellular carcinoma (HCC) patients is related to a poor prognosis. Therefore, identifying high-risk varices (HRV) in HCC patients is crucial. Unlike in cirrhosis, where Baveno VII uses non-invasive tests to rule out HRV, this approach doesn't extend to HCC…
- DateMay 21, 2024Multidrug-resistant bacterial infections (MDR-BI) are emerging problems and associated with poor outcomes in cirrhotic patients. This study aimed to identify risk factors and assess efficacy of empirical antibiotics (ATB) in cirrhotic patients with MDR-BI…